TESARO (TSRO) : On Thursday, The money flowed into the TESARO (TSRO) stock with an uptick to downtick ratio was recorded at 5.42. Transactions worth $0.47 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.09 million. The total money flow into the stock was $0.38 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.1 million of block transactions on upticks. The total money flow in block trades was $0.1 million. In terms of price action, TESARO (TSRO) traded down $0.45 during the session at $84.24. Compared to the previous days closing, the stock was down only by -0.53%. For the week, the stock is -5.03%, over previous weeks closing.
The stock has recorded a 20-day Moving Average of 35.5% and the 50-Day Moving Average is 67.84%. Shares have rallied 47.42% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $93.33 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $53.34 and the 200 Day Moving Average price is recorded at $44.70.
TESARO (NASDAQ:TSRO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $85.75 and $83.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $86.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $86.32, notching a gain of 1.92% for the day. The total traded volume was 767,030 . The stock had closed at $84.69 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Hanke Jeffrey H., Officer (Executive Vp, R&D And Cso) of TESARO, Inc., had unloaded 12,500 shares at an average price of $74.02 in a transaction dated on June 30, 2016. The total value of the transaction was worth $925,250.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.